RxDoctor Payments Data

Douglas Puryear, MD

Sleep Medicine · Midlothian, VANPI 1295768521

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Harmony Biosciences LLC at 57.9% of the total. Reporting peaked in 2023 at $11,713 and has fallen 57.5% since, to $4,982 in 2025. Among sleep medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$48,627in general payments, 2019–2025

Across 715 payments — averaging $68.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$28K
  • Genentech USA, Inc.$9K
  • Jazz Pharmaceuticals Inc.$2K
  • GSK$2K
  • AstraZeneca$1K
  • Inspire Medical Systems, Inc.$985
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$8,60218%
  • Speaking & faculty fees$23,84549%
  • Travel & lodging$2,5005%
  • Food & beverage$12,81226%
  • Education$8682%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,627 in reported general payments places this provider in the 95th percentile of 74 sleep medicine providers in Virginia.

See all sleep medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$833,204
Medicare patients
1,244
Services billed
14,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$22,126
AlvescoCiclesonide15$17,656
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$2,107
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine38$2,100
Albuterol Sulfate HfaAlbuterol Sulfate26$1,064
Armodafinil15$978
Montelukast Sodium60$812
Methylphenidate Hcl11$585
Pramipexole DihydrochloridePramipexole Di-Hcl27$452
Fluticasone Propionate11$376
Clonazepam38$178
Gabapentin12$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$1,727$22,12626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 sleep medicine providers in Virginia.

Other sleep medicine in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →